Citations

Clear

16280 citation(s) found for "Yu, David".

Privacy and dignity for undocumented people? Clinicians’ duties and responses to patient immigration status inquiries
Chooljian, David M. , Baugh, Aaron , DeMartino, Erin S. , Griffith, Matthew F. , Baugh, Aaron D , DeMartino, Erin, Griffith, Matthew , Ely, Eugene Wesley , Akgün, Kathleen M.

Mayo Clinic

Annals of the American Thoracic Society | September 23, 2025 | Volume: 23 | Issue: 1 | Pages: 30-33

10.1513/annalsats.202506-648ip | PMID 40986802 Get It

Practice Patterns in Management of Low‐ to Intermediate‐Grade Salivary Gland Carcinoma: A Multi‐Institutional Study
Sajisevi, Mirabelle , Nguyen, Kenny , Holcomb, Andrew J. , Vural, Emre , Davis, Kyle P. , Thomas, Carissa M. , Stein, John S. , Aulet, Ricardo , Bell, Rebecca K. , Blasco, Michael A., Bowmaster, Vanessa B., Chung, Jeffson , Cognetti, David M. , Cordero, Joehassin , Donovan, John, Du, Yue , Eskander, Antoine , Feinberg, Philip A. , Garvey, Emily A. , Goldstein, David P. , Goulart, Rafael Nunes, Grasl, Stefan , Giurintano, Jonathan , Hara, Jared H. , Hinni, Michael L., Hua, Nadia , Johnson‐Obaseki, Stephanie , Kalman, Noah S. , Khaja, Sobia F. , Ku, Jamie A., Lambert, Arnaud, Luu, Bao K. , Magliocca, Kelly R. , Santos, Luiz Roberto Medina dos , Michael, C. A., Miles, Brett, Melo, Giulianno Molina de , Moore, Michael G. , Moura, Kauê, Noroozi, Hesameddin, Patel, Rusha , Paydarfar, Joseph A. , Plonowska‐Hirschfeld, Karolina A. , Savaria, Fabrice N., Schmitt, Nicole C. , Shapiro, Justin , Stokes, William A. , Sulibhavi, Anita , Vendra, Varun , Vinh, Daniel , Virgen, Celina G. , Woody, N.M. , Young, Geoffrey D., Enepekides, Danny , Hier, Michael , Ryan, William R. , Holcomb, Andrew J , Thomas, Carissa M , Asarkar, Ameya A , Chung, Jeffson , Chan, Kimberly , Chang, Brent A , Dundar, Yusuf , Dedivitis, Rogerio , Goldstein, David , Goyal, Neerav , Grasl, Stefan , Giurintano, Jonathan , Gupta, Nikita , Habib, Andy , Hackman, Trevor , Henson, Christina , Kejner, Alexandra E , de Melo, Giulianno Molina , Morand, Gregoire B , Paydarfar, Joseph , Sadeghi, Nader , Schmitt, Nicole C , Shaver, Timothy B , Tasoulas, Jason , CALLAS, PETER W. , Burruss, Clayton P. , Chang, Brent A. , Coffey, Charles S. , Cooper, Dylan Jacob , Donovan, John, Edwards, Heather , Erović, Boban M. , Goodman, Joseph , Juloori, Aditya , Michael, Cara, Miles, Brett, Morand, Grégoire B. , Stoeckli, Sandro Johannes , Kakarala, Kiran , Davies, Louise

Mayo Clinic

Laryngoscope Investigative Otolaryngology | September 23, 2025 | Volume: 10 | Issue: 5 | Pages: No page available

10.1002/lio2.70246 | PMID 40995062 Get It

ABSTRACT Objectives To characterize practice patterns and outcomes in the management of low‐ and intermediate‐grade salivary gland carcinoma prior to the existence of treatment guidelines. Methods Analysis of a registry of patients who underwent parotid and submandibular gland resections for low‐and intermediate‐grade carcinomas between 2010 and 2019. Results Of all 786 patients included in the study, 726 (92%) had preoperative imaging and 653 (83%) had preoperative biopsy. Of the 729 patients with parotid gland cancer, the majority underwent superficial ( n = 384, 53%) or total ( n = 254, 35%) parotidectomy. In patients with facial nerve preservation, total parotidectomy was associated with a significant increase in transient facial weakness (72/177 (41%) vs. 82/311 (26%), RR 0.65, 95% CI 0.50–0.84, p < 0.05) and permanent facial nerve weakness (23/176 (13%) vs. 16/301 (5%), RR 0.41, 95% CI 0.22–0.75, p < 0.05) compared to superficial parotidectomy. Adjuvant radiation therapy ( RT ) was delivered to 285 (36%) patients. The proportion of patients receiving adjuvant RT declined significantly over the time period from 2015 to 2019 compared to 2010 to 2014 at 162/504 (32%) and 123/282 (44%), respectively ( RR 0.74, 95% CI 0.61–0.89, p < 0.05). When comparing the time periods from 2015 to 2019 and 2010 to 2014, there was no significant difference in local control rates ( RR 0.52, 95% CI 0.26–1.04, p = 0.06) or regional control rates ( RR 0.75, 95% CI 0.26–2.13, p = 0.58). Conclusions Management of low‐ and intermediate‐grade salivary cancer from 2010 to 2019 was variable, which is expected given the rarity and heterogeneity of the disease and the lack of treatment guidelines prior to 2021. Most patients with parotid malignancies underwent superficial or total parotidectomy. The extent of parotidectomy had an impact on facial nerve function outcomes. Delivery of adjuvant radiation trended down with time. The data presented here will support dissemination of the guidelines and provide data that could inform future trials. Level of Evidence 2b.
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology
McDade, Eric , Barthélemy, Nicolas R. , Wang, Guoqiao , Li, Yan , Cao, Yuchen , Clifford, David B., Goate, Alison , Renton, Alan E., Hassenstab, Jason , Perrin, Richard J. , Xiong, Chengjie , Mummery, Catherine J. , Berman, Sarah , Roberson, Erik D. , Dyck, Christopher van , Gauthier, Serge , Masters, Colin L. , Bittner, Tobias , Yaari, R. , Chhatwal, Jasmeer P. , Chrem, Patricio, Xiong, Chengjie , Ringman, John M. , Ryan, Natalie S. , Day, Gregory S. , Daniels, Alisha , Morris, John C., Supnet, Charlene , Team, The DIAN‐TU Study Team and DIAN Obs, McDade, Eric M , Bateman, Randall J , Roberson, Erik , Day, Gregory S , Masters, Colin L , Xiong, Chengjie , Hassenstab, Jason , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Gordon, Brian A. , Benzinger, Tammie L.S. , Renton, Alan , Llibre‐Guerra, Jorge J. , Xiong, Chengjie , Cruchaga, Carlos , Lah, James J. , Masellis, Mario , Brooks, William S. , Suzuki, Kazushi , Jucker, Mathias , Wallon, David , Ikeuchi, Takeshi , Lee, Jae‐Hong , Roh, Jee Hoon , Schofield, Peter R. , Fox, Nick C. , Vöglein, Jonathan , Karch, Celeste M. , Ibanez, Laura , Sánchez‐Valle, Raquel , Morris, John C. , Levey, Allan I. , Bateman, Randall J. , Team, The DIAN‐TU Study Team and DIAN Obs

Mayo Clinic

Alzheimer's & Dementia | September 23, 2025 | Volume: 21 | Issue: 9 | Pages: No page available

10.1002/alz.70689 | PMID 40985290 Get It

Abstract BACKGROUND Tau‐derived cerebrospinal fluid (CSF) biomarkers correlate with amyloid‐beta (Aβ) plaques or tau tangles in Alzheimer's disease (AD). This study assessed the effects of long‐term anti‐Aβ antibodies on amyloid plaques, tau tangles, and CSF tau species to determine the relationships between them. METHODS A post‐hoc analysis of the DIAN‐TU‐001 trial (NCT01760005) examined 142 participants at risk for dominantly inherited AD randomized to solanezumab ( n = 50), gantenerumab ( n = 52), or placebo ( n = 40). High‐resolution mass spectrometry quantified CSF tau species over four years. RESULTS Phosphorylated tau (p‐tau) species (153, 181, 217, 231) increased early in preclinical AD but were reduced with gantenerumab‐mediated Aβ plaque reduction. Nearly a decade later, MTBR‐tau243 and p‐tau205 increased, showing no association with Aβ reduction, aligning with tau tangle pathology progression. DISCUSSION Initially changing soluble p‐tau species track Aβ plaque reduction, while ptau205 and MTBR‐243 reflect tau tangle pathology, informing different pathways of therapeutic strategies. Highlights p‐tau217 and p‐tau231 correlate with Aβ‐PET and respond to Aβ‐plaque lowering therapies. Aβ immunotherapy trials support a direct link between p‐tau changes and Aβ plaques Gantenerumab reduces Aβ plaques but does not affect tau NFT‐related biomarkers. Blood‐based p‐tau217 assays may provide a non‐invasive tool to monitor Aβ therapies. MTBR‐tau243 strongly correlates with tau PET and tracks NFT pathology progression. Further studies are needed to validate tau biomarkers for tracking NFT‐targeting therapies.
Characterizing VEXAS syndrome in women: Findings from an international multicenter study
Lacombe, Valentin , Beck, David B. , Jachiet, Vincent , Comont, Thibault , Heiblig, Maël , Nguyen, Alexandre , Aouba, Achille, Boulu, X. , Curie, Alexandre, Terrier, Benjamin , Bescond, Charles, Kirino, Yohei , Lacombe, Valentin , Beck, David B , Comont, Thibault , Heiblig, Mael , Koster, Matthew, Kirino, Yohei , Mékinian, Arsène , Georgin-Lavialle, Sophie , Bourguiba, Rim , Martín‐Nares, Eduardo , Aouba, Achille , Curie, Alexandre, Koster, Matthew J. , Kosmider, Olivier , Mékinian, A. , Georgin‐Lavialle, Sophie

Mayo Clinic

Journal of Internal Medicine | September 23, 2025 | Volume: 298 | Issue: 5 | Pages: 516-524

10.1111/joim.70023 | PMID 40985189 Get It

AbstractBackgroundVEXAS syndrome is an autoinflammatory disease caused by somatic UBA1 mutations on the X chromosome, predominantly affecting men.ObjectiveTo characterize VEXAS syndrome in women and to compare the features of VEXAS syndrome between sexes.MethodsWe conducted an international, multicenter study, including 12 women and 301 men with genetically confirmed VEXAS syndrome. Data were collected using a standardized case report form. Bone marrow analyses and molecular investigations were performed locally.ResultsClinical features, age at onset, UBA1 mutation type, variant allele frequency, and mortality were comparable between sexes. Acquired X monosomy was found in 6/8 tested women. Additional clonal mutations were present in 3/5 tested women. Three additional UBA1‐mutated women without typical inflammation are described separately.ConclusionVEXAS syndrome affects women with clinical features similar to men, supporting the need for UBA1 testing in women with compatible presentations. X monosomy is common but not universal, suggesting alternative pathogenic mechanisms.
Community-based participatory design of a decade: the FAITH! Cardiovascular Health and Wellness Program
Lalika, Mathias , Kyalwazi, Ashley, Albertie, Monica, Bowie, Janice , Burgess, Ashya, Elegbede, Walé, Erickson, Jamia, Jenkins, Sarah M. , Johnson, Jacquelyn, Krogman, Ashton , Moen, Lainey , Palmer, Michael W. , Penheiter, Sumedha G., Richard, Monisha, Titus, Princess, Schardin, Sueling, Shanedling, Stanton , Hof, Jeremy Van’t , Weis, Jennifer A., Patten, Christi A. , Penheiter, Sumedha, Warner, David, Weis, Jennifer, Brewer, LaPrincess C. , Burke, Lora E. , Buta, Brian J. , Cooper, Lisa A. , Crews, Deidra C. , Doubeni, Chyke A. , Johnson, Jacquelyn, Jones, Clarence , Palmer, Michael, Warner, David O. , Hayes, Sharonne N.

Mayo Clinic

Frontiers in Public Health | September 23, 2025 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fpubh.2025.1622237 | PMID 41063935 Get It

The FAITH! (Fostering African-American Improvement in Total Health) Cardiovascular Health and Wellness Program is more than a decade-long community-based participatory research initiative aimed at addressing cardiovascular health disparities among African-Americans in Minnesota. Founded in 2013, the program employs a culturally tailored, community-driven approach by partnering with African-American faith communities to promote cardiovascular health through education, digital health tools, and multilevel interventions targeting the social determinants of health. Grounded in community-based participatory research principles, FAITH! prioritizes equitable academic-community partnerships, co-learning, community capacity building, and shared ownership in all aspects of research and implementation. The program’s exemplary innovations include the NIH-funded FAITH! Trial, a randomized clinical trial, testing a mobile health intervention (the FAITH! App) co-created with the African-American community, and the Techquity by FAITH! study. Techquity by FAITH! evaluates the effectiveness of a culturally relevant, community-informed mHealth intervention supported by a Digital Health Advocate network to improve overall cardiovascular health and digital health literacy. During its evolution, FAITH! has addressed emergent public health crises, including the COVID-19 pandemic, by adapting programming to provide emergency preparedness resources, health education, and vaccine outreach. Key outcomes include sustainable church-based health ministries, increased research participation, and successful translation of research into practice. The program has also contributed to research workforce development by mentoring and training diverse early-career scholars and community leaders in community-based participatory research and cardiovascular health equity research. Lessons learned highlight the transformative impact of community-based participatory research in building trust, facilitating culturally relevant dissemination, and sustaining health equity initiatives. The FAITH! model demonstrates a scalable, community-led strategy for advancing cardiovascular health in underserved populations and provides a blueprint for future initiatives aiming to reduce racial health disparities.
Pediatric bowling injuries presenting to U.S. emergency departments: a descriptive epidemiologic study
Swanson, Timothy S. , Sugimoto, Dai , Soma, David , Radel, Luke C. , Swanson, Tyra , Radel, Luke, Mikhail, David, Jones, Jacob C.

Mayo Clinic

The Physician and Sportsmedicine | September 22, 2025 | Volume: 53 | Issue: 6 | Pages: 448-455

10.1080/00913847.2025.2565145 | PMID 40982265 Get It

Physeal-Sparing Medial Patellofemoral Ligament Reconstruction With Patellar Tendon Shortening and Guided Growth
Klosterman, Emma L. , Moran, Thomas E. , Tagliero, Adam J. , Bachmann, Keith , Diduch, David R. , Tagliero, Adam , Manley, Brock J. , Ruiz, Abel

Mayo Clinic

Video Journal of Sports Medicine | September 22, 2025 | Volume: 5 | Issue: 5 | Pages: No page available

10.1177/26350254241299455 | PMID 40994927 Get It

Background: In skeletally immature patients, alternative surgical approaches should be undertaken for the treatment of patellofemoral instability that respect the open physis. Remaining growth can be exploited for correction of genu valgum, a known anatomic risk factor of patellofemoral instability. Indications: A skeletally immature 14-year-old boy with bilateral genu valgum and patella alta presented with symptomatic, recurrent left knee patellar instability precluding sports participation and causing dysfunction in his activities of daily living. Technique Description: A midline approach to the knee was used. Medial patellofemoral ligament reconstruction (MPFL-R) was completed up until the point of femoral-sided allograft fixation. The socket for femoral-sided graft fixation was reamed with an all-epiphyseal technique. Next, growth modulation with temporary hemiepiphysiodesis of the medial distal femoral physis was undertaken with an 8-plate bilaterally. Patellar tendon shortening was completed. Femoral-sided graft fixation for the MPFL-R was then completed. Results: There were no acute complications associated with surgery. Surgical management led to resolution of the patient’s patellar instability. The patient is being followed for timing of hemiepiphysiodesis plate removal. Discussion/Conclusion: In skeletally immature patients, a physeal-sparing MPFL-R is a viable treatment option to address recurrent patellar instability. Other anatomic risk factors, such as genu valgum and patella alta, may be concomitantly addressed using techniques that are respective of the open physis. Patient Consent Disclosure Statement: The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.
Cross‐Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease
Abdelmoity, Omar , Wisch, Julie K. , Kennedy, James T. , Vlassenko, Andrei G. , Handen, Benjamin L. , Head, Elizabeth , Lai, Florence , Rosas, H. Diana , Hartley, Sigan L. , Tudorascu, Dana , Keefe, Sarah , Ikeuchi, Takeshi, Morris, John C., Roh, Jee Hoon , Day, Gregory S. , Xiong, Chengjie , Head, Elizabeth , Lao, Patrick , Keefe, Sarah , Roh, Jee Hoon , Day, Gregory S , Gordon, Brian A , Xiong, Chengjie , Wisch, Julie K , Goyal, Manu S. , Flores, Shaney , Keator, David B. , Rafii, Michael S. , Zaman, Shahid H. , Brickman, Adam M. , Lee, Joseph H. , Allegri, Ricardo , Fougère, Christian la , Llibre‐Guerra, Jorge J. , Ikeuchi, Takeshi , Morris, John C. , Schofield, Peter R. , Gordon, Brian A. , Benzinger, Tammie L.S. , Ances, Beau M.

Mayo Clinic

Annals of Neurology | September 22, 2025 | Volume: 98 | Issue: 6 | Pages: 1237-1248

10.1002/ana.78002 | PMID 40977577 Get It

Objectives Directly compare the brain glucose patterns seen with [F‐18] fluorodeoxyglucose (FDG) positron emission tomography (PET) between 2 genetically determined forms of Alzheimer's disease: Down syndrome (DS) and autosomal dominant Alzheimer's disease (ADAD). Methods Cross‐sectional analyses of FDG were performed in individuals with DS (n = 76) from the Alzheimer Biomarker Consortium‐Down Syndrome (ABC‐DS), ADAD (n = 297), and neurotypical familial controls (n = 188) from the Dominantly Inherited Alzheimer Network (DIAN). Within‐group linear regression models and generalized additive models were performed for select regional FDG uptake measures (isthmus cingulate and inferior parietal, precuneus, middle temporal gyrus, and precentral gyrus). Age, sex, apolipoprotein (APOE) ε4 carrier status, and cortical amyloid burden were included within these analyses. Results Even 20 years before expected onset of clinical symptoms, FDG uptake was lower for DS compared to neurotypical familial controls ( p < 0.01). ADAD baseline FDG was similar to neurotypical familial controls until 7 years before expected symptom onset. Both symptomatic individuals with DS and ADAD had lower FDG compared to neurotypical familial controls ( p < 0.01). A higher amyloid burden was associated with lower FDG for both genetic forms, with similar rates of decline in FDG uptake for DS and ADAD who were amyloid positive. Interpretation Brain glucose metabolism is substantially lower for people with DS, even in individuals who are cognitively stable. The patterns of FDG decline are distinct in these 2 genetically determined forms of AD. The diagnostic utility of FDG‐PET is specific to the genetic form of AD. ANN NEUROL 2025;98:1237–1248
Opioid prescribing trends and pain scores among adult patients with cancer in a large health system
Baum, Laura Van Metre , Soulos, Pamela R. , Ruddy, Kathryn J. , Lerro, Catherine C. , Graham, David J. , Rivera, Donna R. , Liberatore, Mark, Jairam, Vikram , Gross, Cary P. , Park, Henry S. , Ruddy, Kathryn J , Leapman, Michael S , Gross, Cary P , Park, Henry S , KC, Madhav , Jeffery, Molly Moore , Lee, Hana , Leapman, Michael , Dinan, Michaela A.

Mayo Clinic

Cancer | September 22, 2025 | Volume: 131 | Issue: 19 | Pages: No page available

10.1002/cncr.70027 | PMID 40977160 Get It

Abstract Background Opioid stewardship policies could adversely affect pain management for patients with cancer. Yet patients with cancer are also at risk for opioid‐related harms. This study sought to determine trends in opioid prescribing by clinical stratum and pain for patients with cancer from 2016 to 2020. Methods A retrospective study was conducted of opioid‐naive adults with newly diagnosed cancer from 2016 to 2020 ( N = 10,232) in a large Connecticut health system. Logistic regression was used to calculate changes in the predicted probability of opioid prescribing from 2016 to 2020. Two subpopulations were examined: patients treated surgically ( n = 4405) and patients with metastatic cancer ( n = 2158). Flowsheet pain scores for patients with metastatic cancer were used to stratify by no pain (all scores, 0) versus any pain. The main outcomes were new (≥1 prescription in the 0–6 months after diagnosis) and additional (0–6 and 7–9 months) opioid prescriptions. Results A decline was observed in the predicted probability of new (71.1% to 64.6%; p < .001) and additional prescribing (27.2% to 24.2%; p = .07 [not significant]) declined. Among surgical patients, the predicted probability of new opioid prescribing fell (96.0% to 88.6%; p < .001), whereas additional prescribing was stable (13%). For patients with metastatic cancer with pain, new opioid prescribing was stable (56%). For those reporting no pain, the predicted probability of new opioid prescribing declined from 61.6% to 36.1% ( p < .001). Conclusions In the context of widespread policy changes, this study showed a modest decline in new and additional opioid prescribing for patients with cancer. In metastatic cancer, prescribing remained stable for patients reporting pain and declined steeply for those reporting no pain.
Telestroke and Emergency Department Imaging: Timing of CT Angiography Within the IV Thrombolytic Decision-Making Sequence
Murray, Nick M. , McKasson, Marilyn , Johnson, Paul D. , Johnson, Trina, Hassler, Jami, Smith, Shawn , Hoesch, Robert, Guidry, David, Johnston, Chamonix, Püttgen, H. Adrian , Johnson, Trina, Demaerschalk, Bart M. , Johnston, Chamonix

Mayo Clinic

The Neurohospitalist | September 20, 2025 | Volume: 16 | Issue: 2 | Pages: 133-139

10.1177/19418744251382291 | PMID 40979633 Get It

Background Telestroke emergency department (ED) workflow emulates that of in-person care, yet limitations of the virtual interaction may require accommodations. The optimal sequence of non-contrast head CT, cerebral CT angiogram, and decision to infuse IV thrombolytic is not defined for telestroke. Methods In this twenty-two-hospital multicenter retrospective study between 1/1/2024-12/31/2024, we characterized timing of ED CT angiograms, either bundled with the non-contrast head CT or non-bundled and performed after the IV-thrombolytic decision. The primary outcome was effect of bundling on door to needle time (DTN) when directed by telestroke. Timing of CT scans was determined by time stamps of scout images. Results In total, 5704 patients were included, with a median age of 65 years (Interquartile range, IQR 58-77) and NIHSS 8 (IQR 6-13). There were 4518 patients in the bundled group (n = 12 hospitals), with time from non-contrast CT to CTA of median 2 min (IQR 0-6 min; vs non-bundled (n = 10 hospitals): 7, 4-15 min; P = .0001). DTN was not statistically different between the groups, bundled vs not: median 47 min (IQR, 35-62 min) vs 54 min (IQR, 41-67 min, P = .21). Door in door out (DIDO) times also were unchanged (169, 117-254 vs 175, 123-247 min; P = .56). These findings, although showing no statistical difference, may have significance for clinical workflows and were consistent with the results of validation analyses conducted on individual patients. Conclusions Bundling non-contrast head CT with the CT angiogram before thrombolytic decision did not delay DTN times, trended to clinically improve times, and may be relevant for telestroke ED workflows.